Tiziana Life Sciences (TILS)


Latest News

Tiziana says development of oral formulation of foralumab to be used in clinical studies

Tiziana Life Sciences announced the development of a novel, proprietary, oral formulation of foralumab, a fully human ...

A Proprietary Oral Formulation of Foralumab

RNS Number: 8848P Tiziana Life Sciences PLC 06 September 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH Successfully developed a novel formulation enabling oral immunotherapy with foraluma...

Grant of options - Director's dealing

RNS Number: 4431P Tiziana Life Sciences PLC 31 August 2017 Tiziana Life Sciences PLC ("Tiziana" or the "Company") Grant of options - Director's dealing London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that ...

Tiziana converts loan notes to shares

Tiziana Life Sciences, a clinical stage biotechnology company, said holders of the company's convertible loan note (CLN) h...

All News

06-09-17Tiziana says development of oral formulation of foralumab to be used in clinical studiesStockMarketWire
06-09-17A Proprietary Oral Formulation of ForalumabRNS
31-08-17Grant of options - Director's dealingRNS
16-08-17Tiziana converts loan notes to sharesStockMarketWire
16-08-17Conversion of outstanding loan notesRNS
28-07-17Publication of Research Article on ForalumabRNS
19-07-17Tiziana enrols first patient in Phase IIa clinical trialStockMarketWire
19-07-17Initiation of a Phase IIa Clinical TrialRNS
12-07-17Proposed changes to CLNs and Warrant TermsRNS
29-06-17Result of AGMRNS
12-06-17Appointment of Dr Kunwar Shailubhai as CEORNS
08-06-17Bcl-3 pre-clinical update and Director's dealingRNS
01-06-172016 Annual Report and Accounts and notice of AGMRNS
23-05-17Financial Results for Year Ended 31 December 2016RNS
24-04-17Broker Forecast - Beaufort Securities issues a broker note on Tiziana Life Sciences Plc Ord 3pStockMarketWire
24-04-17TILS confirms Phase II clinical trial protocol for Milciclib StockMarketWire
24-04-17Announces Approval of a Phase II Clinical TrialRNS
21-04-17Announces Publication of Milciclib Clinical TrialRNS
24-03-17Tiziana Life Sciences notes exercise of warrantsStockMarketWire
24-03-17Exercise of Warrants & Issue of EquityRNS
14-03-17Arun Sanyal appointed to Scientific Advisory BoardRNS
16-01-17Warrant Expiry - ReminderRNS
03-01-17Tiziana Life Sciences in-licences NI-1201StockMarketWire
03-01-17Tiziana Life Sciences in-licenses NI-1201RNS
16-11-16Tiziana announces new data with ForalumabStockMarketWire
16-11-16New Data with ForalumabRNS
07-11-16Tiziana CFO awarded options StockMarketWire
07-11-16Grant of optionsRNS
29-09-16Half-year ReportRNS
15-09-16Confirmation of Capital ReductionRNS
18-08-16Change of Registered OfficeRNS
18-07-16Tiziana acquires a unique bio-repositoryStockMarketWire
18-07-16Tiziana acquires a unique bio-repositoryRNS
30-06-16Result of AGMRNS
29-06-16Issue of EquityRNS
10-06-16Grant of options and realisation bonusRNS
07-06-16Tiziana Life Sciences widens FY pretax lossStockMarketWire
07-06-16Final ResultsRNS
01-06-16Partnership with Cardiff Researchers Wins AwardRNS

RSS feeds

  • Editorial news feed for LSE:TILS Editorial
  • Regulatory news feed for LSE:TILS Regulatory